Skip to content
Glutethimide
Doriden (glutethimide) is a small molecule pharmaceutical. Glutethimide was first approved as Doriden on 1982-01-01. It is used to treat sleep initiation and maintenance disorders in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glutethimide
Tradename
Company
Number
Date
Products
DORIDENSanofiN-009519 DISCN1982-01-01
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
sleep initiation and maintenance disorders—D007319F51.01
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05C: Hypnotics and sedatives
— N05CE: Piperidinedione derivatives, hypnotics and sedatives
— N05CE01: Glutethimide
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—12——1114
AtherosclerosisD050197EFO_0003914I25.1———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary diseaseD003327—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Smoking cessationD016540EFO_0004319—1———1
Tobacco use disorderD014029F17—1———1
Cardiovascular diseasesD002318EFO_0000319I98—1———1
Myocardial ischemiaD017202EFO_1001375I20-I25—1———1
Heart diseasesD006331EFO_0003777I51.9—1———1
AlcoholismD000437EFO_0003829F10.1—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug interactionsD0043473————3
Type 2 diabetes mellitusD003924EFO_0001360E112————2
NeoplasmsD009369C801————1
PharmacokineticsD0105991————1
Hiv infectionsD015658EFO_0000764B201————1
Alzheimer diseaseD000544EFO_0000249F031————1
AnemiaD000740EFO_0004272D64.91————1
Biological availabilityD0016821————1
HypertriglyceridemiaD015228EFO_00042111————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGLUTETHIMIDE
INNglutethimide
Description
Glutethimide is a hypnotic sedative that was introduced by Ciba in 1954 as a safe alternative to barbiturates to treat insomnia. Before long, however, it had become clear that glutethimide was just as likely to cause addiction and caused similar withdrawal symptoms. Doriden was the brand-name version. Current production levels in the United States (the annual quota for manufacturing imposed by the DEA has been three grams, enough for six Doriden tablets, for a number of years) point to it being used only in small scale research. Manufacturing of the drug was discontinued in the US in 1993 and discontinued in several eastern European countries in 2006.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC1(c2ccccc2)CCC(=O)NC1=O
Identifiers
PDB—
CAS-ID77-21-4
RxCUI4903
ChEMBL IDCHEMBL1102
ChEBI ID5439
PubChem CID3487
DrugBankDB01437
UNII IDC8I4BVN78E (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 617 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
46,981 adverse events reported
View more details